Transdermal absorption beta-nicotinamide mononucleotide nano-liposome as well as preparation method and application thereof
By preparing β-nicotinamide single nucleotide nanoliposomes with particle size of 72-107 nm, combined with TPGS modification and high-pressure homogenization treatment, the problems of nanoliposome stability and low encapsulation rate were solved, and the further development was achieved The high cellular uptake rate and anti-aging effects have expanded its application in medicines and skin care products.
Patent Information
- Application Number
- CN202410997308.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-15
AI Technical Summary
The existing β-nicotinamide single nucleotide nanoliposomes have poor stability, unclear functional components, low encapsulation rate and large particle size, which makes the active substance difficult to be absorbed.
Transdermal absorption nanoliposomes prepared using components such as β-nicotinamide single nucleotides, phospholipids, cholesterol, polyethylene glycol vitamin E succinate, sodium cholate and isopropyl myristate, and are phacoemulsified by phacoemulsification. With high pressure homogenization treatment, nanoliposomes with particle sizes of 72-107 nm were formed, and the stability and encapsulation rate were improved through TPGS modification.
It significantly improves the stability and cellular uptake rate of nanoliposomes, enhances the penetration efficiency of active ingredients, extends the action time, improves the anti-aging effect, and expands its application range in medicines and skin care products.
Smart Images

Figure CN118948767A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nanoliposomes, and in particular to a transdermal β-nicotinamide mononucleotide nanoliposome and a preparation method and application thereof. Background Art
[0002] Aging is an irreversible law of nature, making delaying aging a focus of continuous attention in the scientific community. β-Nicotinamide mononucleotide (NMN) is a biologically active nucleotide that is commonly found in various organisms. It is a direct precursor of coenzyme I (NAD+), and the level of NAD+ can be increased through supplementation. NAD+ is associated with human health and aging. It is an indispensable key coenzyme in many biochemical reactions in the body. It participates in important biological oxidation and energy metabolism processes such as glycolysis, tricarboxylic acid cycle (TCA), gluconeogenesis (pentose phosphate pathway), fat β-oxidation, ketone body production and amino acid metabolism, and directly or indirectly affects cell functions such as DNA repair, chromatin remodeling, cell aging and cell immunity. However, NAD+ cannot be absorbed by the human body and cannot be supplemented by direct ingestion. Therefore, supplementing exogenous NMN can be used as an effective alternative. It can effectively increase the concentration of NAD+ in cells, and the stability of NMN is easily affected by environmental conditions, making it difficult to ensure the effectiveness and safety of the product. Polyethylene glycol vitamin E succinate (TPGS) is a water-soluble derivative of vitamin E and a non-ionic surfactant. It can be used as a solubilizer and absorption enhancer in drug delivery systems to increase the absorption of drugs in the gastrointestinal tract and improve the bioavailability of drugs. Therefore, it is necessary to develop a liposome with stable performance and clear efficacy to expand its application range.
[0003] The prior art with publication number CA 104042569 A discloses a method for preparing a polyethylene glycol vitamin E succinate modified curcumin chloride chitosan liposome, comprising: weighing curcumin, phospholipids, cholesterol, and polyethylene glycol vitamin E succinate, mixing and reacting to prepare liposomes, and then adding chloride chitosan to obtain polyethylene glycol vitamin E succinate modified curcumin chloride chitosan liposomes with an average particle size of 341 nm and an average encapsulation efficiency of 89.31%.
[0004] However, the liposomes prepared as above have the following problems: first, the binding between the components is weak, resulting in poor stability of the liposomes; second, there are many types of components and the effective ingredients are unclear; third, the liposomes have a low encapsulation rate and large particle size, resulting in the active substances being difficult to be absorbed. Summary of the invention
[0005] The present application discloses a transdermal β-nicotinamide mononucleotide nanoliposome and its preparation method and application, aiming to solve the technical problems of existing liposomes such as poor stability, unclear effective ingredients, low encapsulation rate, and large particle size.
[0006] In order to achieve the above purpose, the technical solution of this application is:
[0007] The first aspect of the present application provides a transdermal β-nicotinamide mononucleotide nanoliposome, the components of which, calculated by the total mass percentage of the raw materials, include:
[0008] β-Nicotinamide mononucleotide 7-25%,
[0009] Phospholipids 3-5%,
[0010] Cholesterol 10-25%,
[0011] Macrogol Vitamin E Succinate 40-60%,
[0012] Sodium cholate 3-10%,
[0013] Isopropyl myristate 0.1-0.3%,
[0014] The balance is water to make up to 100%;
[0015] The particle size of the transdermal β-nicotinamide mononucleotide nanoliposome is 72-107 nm.
[0016] In combination with the first aspect, preferably, the phospholipid is one or more of soybean lecithin, egg yolk lecithin, dipalmitoylphosphatidylcholine, dilauroylphosphatidylcholine, and distearoylphosphatidylcholine.
[0017] In combination with the first aspect, preferably, the mass ratio of the β-nicotinamide mononucleotide to the phospholipid is 1:4-15;
[0018] And / or, the mass ratio of the vitamin E polyethylene glycol succinate to the phospholipid is 1:10-30;
[0019] And / or, the mass ratio of cholesterol to phospholipid is 1:4-10;
[0020] And / or, the mass ratio of β-nicotinamide mononucleotide to sodium cholate is 1:4;
[0021] And / or, the mass ratio of β-nicotinamide mononucleotide to isopropyl myristate is 1:2.
[0022] The second aspect of the present application provides a method for preparing the transdermal β-nicotinamide mononucleotide nanoliposomes described in the first aspect, the method comprising:
[0023] Dissolve phospholipids, cholesterol and polyethylene glycol vitamin E succinate in anhydrous ethanol, and perform vacuum rotary evaporation once to obtain a lipid film;
[0024] Mixing sodium cholate, isopropyl myristate, the primary lipid film and anhydrous ethanol, and performing secondary reduced-pressure rotary evaporation to obtain a secondary lipid film;
[0025] The aqueous solution of β-nicotinamide mononucleotide is mixed with the secondary lipid film, a phosphate buffer solution is added, ultrasonic emulsification dispersion and mixing is performed in an ice water bath, and high-pressure homogenization is performed to obtain the transdermally absorbable β-nicotinamide mononucleotide nanoliposome.
[0026] In combination with the second aspect, preferably, the rotation speed of the first vacuum rotary evaporation and the second vacuum rotary evaporation is 45 r / min, the pressure is 0.10 MPa, and the temperature is 40-50°C.
[0027] In combination with the second aspect, preferably, during the ultrasonic emulsification dispersion mixing in the ice-water bath, the emulsification power is 150-250 W, the emulsification frequency is ultrasonic 4 s, the interval is 2 s, and the emulsification time is 2-4 min.
[0028] In combination with the second aspect, preferably, the pressure of the high-pressure homogenization treatment is 600-800 bar.
[0029] In combination with the second aspect, preferably, the number of cycles of the high-pressure homogenization treatment is 2-3 times.
[0030] In combination with the second aspect, preferably, the concentration of the phosphate buffer solution is 0.05 mol / L and the pH is 6.0-7.0.
[0031] The third aspect of the present application provides the use of the transdermal β-nicotinamide mononucleotide nanoliposomes prepared by the preparation method of the second aspect in the preparation of medicines and skin care products.
[0032] Compared with the prior art, the advantages or beneficial effects of the embodiments of the present application include at least:
[0033] The transdermal β-nicotinamide mononucleotide nanoliposomes provided in the present application are transdermal β-nicotinamide mononucleotide nanoliposomes with a particle size of 72-107 nm made from raw materials including: β-nicotinamide mononucleotide (NMN), phospholipids, cholesterol, polyethylene glycol vitamin E succinate (TPGS), sodium cholate, isopropyl myristate and water. On the one hand, modifying the surface of NMN nanoliposomes by TPGS can not only protect NMN from inactivation due to environmental influences, thereby ensuring the stability of the active ingredient content in the product, but also effectively improve the encapsulation rate and cellular uptake rate of nanoliposomes, while further enhancing the stability of liposomes; on the second hand, it can reduce the interfacial tension between liposomes and biological membranes, enhance the penetration efficiency of active ingredients, improve the transdermal penetration bioavailability and skin retention of NMN, and achieve sustained and controlled release, prolong the action time, and significantly enhance the anti-aging effect of NMN; on the third hand, it can adsorb, exchange lipids, and fuse with cells, thereby increasing the efficiency of NMN penetrating cells and enhancing product efficacy, and has good water dispersibility, and can be arbitrarily compatible with various preparations to expand its scope of application. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments recorded in the present application, and for ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0035] Figure 1 The results of in vitro release studies of α1-α4 transdermal β-nicotinamide mononucleotide nanoliposomes prepared in Examples 1-4 of the present application and B1-B2 liposomes prepared in Comparative Examples 1-2;
[0036] Figure 2 The results of the cell absorption rate test of the α1-α4 transdermal β-nicotinamide mononucleotide nanoliposomes prepared in Examples 1-4 of the present application and the B1-B2 liposomes prepared in Comparative Examples 1-2;
[0037] Figure 3 This is a result diagram showing the effect of the α1-α4 transdermal β-nicotinamide mononucleotide nanoliposomes prepared in Examples 1-4 of the present application and the B1-B2 liposomes prepared in Comparative Example 1-2 on improving H2O2 oxidative damage in HaCaT cells;
[0038] Among them, the comparison between H2O2 group and blank group####P<0.0001; compared with H2O2 group*P<0.05,**P<0.01,***P<0.005,****P<0.0001;
[0039] Figure 4 The results of the human dermal fibroblast β-galactosidase staining experiment of the α1-α4 transdermal β-nicotinamide mononucleotide nanoliposomes prepared in the examples of the present application and the B1-B2 liposomes prepared in comparative examples 1-2;
[0040] Figure 5 This is a graph showing the results of the ABTS free radical scavenging experiment of the α1-α4 transdermal β-nicotinamide mononucleotide nanoliposomes prepared in the examples of the present application and the B1-B2 liposomes prepared in comparative examples 1-2. DETAILED DESCRIPTION
[0041] The technical solutions in the embodiments of the present application will be described clearly and completely below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, rather than all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.
[0042] In the following description of this embodiment, the term "and / or" is used to describe the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can represent: A exists alone, B exists alone, and A and B exist at the same time. A and B can be singular or plural. The character " / " generally indicates that the associated objects before and after are in an "or" relationship.
[0043] In the following description of this embodiment, the term "at least one" refers to one or more, and "plurality" refers to two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b or c", or "at least one of a, b and c", can all represent: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, c can be single or multiple, respectively.
[0044] Those skilled in the art should understand that in the following description of the embodiments of the present application, the order of serial numbers does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.
[0045] The terms used in the embodiments of the present application are only for the purpose of describing specific embodiments, and are not intended to limit the present application. The singular forms "a", "an" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.
[0046] Unless otherwise specified, all raw materials and reagents used in the examples of the present application are purchased on the market or prepared according to conventional methods well known to those skilled in the art, for example, polyethylene glycol vitamin E succinate (TPGS), β-nicotinamide mononucleotide (NMN), cholesterol, sodium cholate, etc. are purchased on the market or prepared according to conventional methods well known to those skilled in the art.
[0047] In a first aspect, the present invention provides a transdermal β-nicotinamide mononucleotide nanoliposome, the components of which, calculated by the total weight percentage of the raw materials, include:
[0048] β-Nicotinamide mononucleotide 7-25%,
[0049] Phospholipids 3-5%,
[0050] Cholesterol 10-25%,
[0051] Macrogol Vitamin E Succinate 40-60%,
[0052] Sodium cholate 3-10%,
[0053] Isopropyl myristate 0.1-0.3%,
[0054] The balance is water to make up to 100%;
[0055] The particle size of the transdermal β-nicotinamide mononucleotide nanoliposome is 72-107 nm.
[0056] Among them, on the one hand, modifying the surface of β-nicotinamide mononucleotide nanoliposomes by polyethylene glycol vitamin E succinate can not only protect NMN from inactivation due to environmental influences, thereby ensuring the stability of the active ingredient content in the product, but also effectively improve the encapsulation rate and cellular uptake rate of nanoliposomes, while further enhancing the stability of liposomes; on the second hand, it can reduce the interfacial tension between liposomes and biological membranes, enhance the penetration efficiency of active ingredients, improve the transdermal penetration bioavailability and skin retention of NMN, and achieve sustained and controlled release, prolong the action time, and significantly enhance the anti-aging effect of NMN; on the third hand, it can adsorb, exchange lipids, and fuse with cells, increase the efficiency of NMN penetrating cells, enhance product efficacy, and has good water dispersibility, and can be arbitrarily compatible with various preparations to expand its application range.
[0057] In the embodiment of the present application, the phospholipid is one or more of soybean lecithin, egg yolk lecithin, dipalmitoylphosphatidylcholine, dilauroylphosphatidylcholine, and distearoylphosphatidylcholine. Among them, through the selection of these phospholipids, stable liposomes can be formed with cholesterol.
[0058] The second aspect of the present application provides a method for preparing the transdermal β-nicotinamide mononucleotide nanoliposomes described in the first aspect, the method comprising:
[0059] Dissolve phospholipids, cholesterol and polyethylene glycol vitamin E succinate in anhydrous ethanol, and perform vacuum rotary evaporation once to obtain a lipid film;
[0060] Mixing sodium cholate, isopropyl myristate, the primary lipid film and anhydrous ethanol, and performing secondary reduced-pressure rotary evaporation to obtain a secondary lipid film;
[0061] The aqueous solution of β-nicotinamide mononucleotide is mixed with the secondary lipid film, a phosphate buffer solution is added, ultrasonic emulsification dispersion and mixing is performed in an ice water bath, and high-pressure homogenization is performed to obtain the transdermally absorbable β-nicotinamide mononucleotide nanoliposome.
[0062] It should be noted that ultrasonic dissolution technology is a technology that uses the cavitation effect, mechanical effect and thermal effect of ultrasound to improve the solubility of substances. It is highly efficient, energy-saving and environmentally friendly. Ultrasonic emulsification technology can prepare liposomes with uniform particle size distribution. The consistency of particle size directly affects the stability and release characteristics of liposomes. Liposomes prepared using ultrasonic emulsification technology have a high encapsulation rate, ensuring that more NMN active ingredients are encapsulated inside the liposomes, and are easy to operate, which is conducive to large-scale and continuous production.
[0063] It should be noted that the modification of vitamin E polyethylene glycol succinate (TPGS) effectively improves the encapsulation rate and cellular uptake rate of nanoliposomes. Since its molecular structure contains vitamin E with antioxidant properties, TPGS further enhances the stability of nanoliposomes. TPGS can also reduce the interfacial tension between liposomes and biological membranes and enhance the penetration efficiency of active ingredients. TPGS-modified liposomes can also avoid being engulfed by the reticuloendothelial system and prolong the circulation time of liposomes.
[0064] It should be noted that sodium cholate can reduce the interfacial tension between water and oil, and can form small molecule micelles together with phospholipids to improve the encapsulation efficiency. Isopropyl myristate can be mixed with water to form a latent solvent, which helps to include free active molecules in the form of micelles or emulsions.
[0065] It should be noted that high-pressure homogenization can reduce the particle size of the dispersed phase in the material, obtain fine and uniform particles, provide better stability, improve storage quality, improve homogeneity, improve absorption quality, save expensive additives, change viscosity and reduce reaction time.
[0066] The third aspect of the present application provides the use of the transdermal β-nicotinamide mononucleotide nanoliposomes prepared by the preparation method of the second aspect in the preparation of medicines and skin care products. The transdermal β-nicotinamide mononucleotide nanoliposomes have excellent product stability, small particle size, high encapsulation rate, good anti-aging effect, strong stability, and good transdermal absorption, thereby giving the product excellent product competitiveness.
[0067] The technical solution of the present application will be further described below in conjunction with specific embodiments.
[0068] Example 1
[0069] This embodiment provides a method for preparing α1-transdermal β-nicotinamide mononucleotide nanoliposomes, which specifically includes:
[0070] S101: Weigh 120 mg of soybean lecithin, 20 mg of cholesterol and 10 mg of TPGS into a round-bottom flask, add 20 ml of anhydrous ethanol and ultrasonically dissolve, connect the round-bottom flask to a rotary evaporator, and evaporate the organic solvent under reduced pressure at 50°C, 45 r / min, and 0.10 MPa to obtain a uniform lipid film A1 attached to the flask wall;
[0071] S102: Continue to add 60 mg of sodium cholate and 30 mg of isopropyl myristate to the round-bottom flask, then add 10 ml of anhydrous ethanol to fully dissolve by ultrasonication, and evaporate under reduced pressure at 40°C, 45 r / min, and 0.10 MPa to obtain a uniform lipid film B1;
[0072] S103: Weigh 15 mg of NMN, add 8 ml of deionized water and ultrasonically dissolve it, pour 8 ml of NMN aqueous solution and 10 ml of phosphate buffer solution (concentration of 0.05 mol / L, pH 6.5) into the container containing the lipid film B1, perform ultrasonic emulsification dispersion mixing, ultrasonicate at 200 W power for 3 min (intermittent ultrasonication, 4s / 2s) in an ice water bath, and then perform high-pressure homogenization treatment at 700 bar for 3 times to obtain the α1-transdermal β-nicotinamide mononucleotide nanoliposomes.
[0073] Example 2
[0074] This embodiment provides a method for preparing α2-transdermal β-nicotinamide mononucleotide nanoliposomes, which specifically includes:
[0075] S201: Weigh 120 mg of egg yolk lecithin, 20 mg of cholesterol and 5 mg of TPGS into a round-bottom flask, add 20 ml of anhydrous ethanol and ultrasonically dissolve, connect the round-bottom flask to a rotary evaporator, and evaporate the organic solvent under reduced pressure at 50°C, 45 r / min, and 0.10 MPa to obtain a uniform lipid film A2 attached to the flask wall;
[0076] S202: Continue to add 60 mg of sodium cholate and 30 mg of isopropyl myristate to the round-bottom flask, then add 10 ml of anhydrous ethanol to fully dissolve by ultrasonication, and evaporate under reduced pressure at 40°C, 45 r / min, and 0.10 MPa to obtain a uniform lipid film B2;
[0077] S203: Weigh 15 mg of NMN, add 8 ml of deionized water and ultrasonically dissolve it, pour 8 ml of NMN aqueous solution and 10 ml of phosphate buffer solution (concentration of 0.05 mol / L, pH 6.5) into the container containing the lipid film B2, perform ultrasonic emulsification dispersion mixing, ultrasonicate at 200 W power for 3 min (intermittent ultrasonication, 4s / 2s) in an ice water bath, and then perform high-pressure homogenization treatment at 700 bar for 3 times to obtain the α2-transdermal β-nicotinamide mononucleotide nanoliposomes.
[0078] Example 3
[0079] This embodiment provides a method for preparing α3-transdermal β-nicotinamide mononucleotide nanoliposomes, which specifically includes:
[0080] S301: 80 mg of dilauroylphosphatidylcholine, 20 mg of cholesterol and 8 mg of TPGS were weighed into a round-bottom flask, and 20 ml of anhydrous ethanol was added for ultrasonic dissolution. The round-bottom flask was connected to a rotary evaporator, and the organic solvent was removed by reduced pressure evaporation at 50°C, 45 r / min, and 0.10 MPa to obtain a uniform lipid film A3 attached to the flask wall;
[0081] S302: Continue to add 80 mg of sodium cholate and 40 mg of isopropyl myristate to the round-bottom flask, then add 10 ml of anhydrous ethanol to fully dissolve by ultrasonication, and evaporate under reduced pressure at 40°C, 45 r / min, and 0.10 MPa to obtain a uniform lipid film B3;
[0082] S303: Weigh 20 mg of NMN, add 10 ml of deionized water and ultrasonically dissolve it, pour 10 ml of NMN aqueous solution and 10 ml of phosphate buffer solution (concentration of 0.05 mol / L, pH 6.0) into the container containing the lipid film B3, perform ultrasonic emulsification dispersion mixing, ultrasonicate at 150 W power for 4 min (intermittent ultrasonication, 4s / 2s) in an ice water bath, and then perform high-pressure homogenization treatment twice at 800 bar to obtain the α3-transdermal β-nicotinamide mononucleotide nanoliposomes.
[0083] Example 4
[0084] This embodiment provides a method for preparing α4-transdermal β-nicotinamide mononucleotide nanoliposomes, which specifically includes:
[0085] S401: 120 mg soybean lecithin, 12 mg cholesterol and 4 mg TPGS were weighed into a round-bottom flask, and 20 ml anhydrous ethanol was added for ultrasonic dissolution. The round-bottom flask was connected to a rotary evaporator, and the organic solvent was removed by reduced pressure evaporation at 50°C, 45 r / min, and 0.10 MPa to obtain a uniform lipid film A4 attached to the flask wall;
[0086] S402: Continue to add 32 mg of sodium cholate and 16 mg of isopropyl myristate to the round-bottom flask, then add 10 ml of anhydrous ethanol to fully dissolve by ultrasonication, and evaporate under reduced pressure at 40°C, 45 r / min, and 0.10 MPa to obtain a uniform lipid film B4;
[0087] S403: 8 mg of NMN was weighed, and 4 ml of deionized water was added for ultrasonic dissolution. 4 ml of the NMN aqueous solution and 10 ml of phosphate buffer solution (concentration of 0.05 mol / L, pH 6.0) were poured into the container containing the lipid film B4, and ultrasonic emulsification dispersion mixing was performed. Ultrasound was performed in an ice water bath at a power of 250 W for 2 min (intermittent ultrasound, 4s / 2s), and then high-pressure homogenization was performed at 600 bar for 3 times to obtain the α4-transdermal β-nicotinamide mononucleotide nanoliposomes.
[0088] At the same time, in order to verify the comprehensive performance of the transdermal β-nicotinamide mononucleotide nanoliposomes prepared in the above examples, the present application provides the following comparative examples for detailed description.
[0089] Comparative Example 1
[0090] The component ratio, preparation operation and process parameters of the B1-liposome prepared in this comparative example are basically the same as those in Example 1, except that polyethylene glycol vitamin E succinate is not added in this comparative example to prepare the B1-liposome.
[0091] Comparative Example 2
[0092] The component ratio, preparation operation and process parameters of the B2-liposome prepared in this comparative example are basically the same as those in Example 1, except that polyethylene glycol vitamin E succinate, sodium cholate and isopropyl myristate are not added in this comparative example to prepare the B2-liposome.
[0093] In order to verify the comprehensive performance of the liposomes prepared in the examples of the present application, corresponding performance tests were performed. The liposomes prepared in the above examples 1-4 and comparative examples 1-2 were subjected to performance tests:
[0094] Test 1: Test average particle size, Zeta potential, PDI and encapsulation efficiency
[0095] The hydrodynamic particle size, Zeta potential and polydispersity index (PDI) of the liposomes were determined by dynamic light scattering technology. The liposomes prepared in Examples 1-4 and Comparative Examples 1-2 were used as samples. After being diluted to a certain concentration with deionized water, the samples were measured three times in parallel at 25°C, and the average particle size, Zeta potential and PDI of the samples were recorded. The encapsulation efficiency was determined by high performance liquid chromatography (HPLC), and the encapsulation efficiency was calculated after liquid phase analysis. The results are shown in Table 1.
[0096] Table 1 Test results of average particle size, Zeta potential, PDI and encapsulation efficiency
[0097] Group Particle size / nm PDI Zeta potential / mV Encapsulation rate / % Example 1 72 0.24 31.2 95.3 Example 2 84 0.23 30.8 92.6 Example 3 89 0.26 31.3 89.8 Example 4 107 0.25 29.9 88.1 Comparative Example 1 121 0.46 10.6 76.5 Comparative Example 2 139 0.43 12.4 68.1
[0098] Zeta potential and PDI are key parameters for evaluating the stability and uniformity of particle dispersion systems. High absolute Zeta potential and low PDI values usually mean better dispersibility and stability. As shown in Table 1, the average particle size of the liposomes modified with polyethylene glycol vitamin E succinate is reduced, the Zeta potential is increased, the polydispersity index PDI is significantly reduced, the particle stability is increased, and the encapsulation efficiency is improved. The liposomes prepared in Example 1 have the smallest particle size, the highest encapsulation efficiency, the best dispersibility and stability, and the most stable performance. The test results show that the transdermal β-nicotinamide mononucleotide nanoliposomes provided in the present application can encapsulate more NMN and retain its activity to the greatest extent, avoiding a large amount of loss and improving the utilization rate.
[0099] Test 2: Stability test
[0100] The liposomes prepared in the above Examples 1-4 and Comparative Examples 1-2 were placed in a sealed container and placed at -18°C, 4°C, room temperature and 45°C for 180 days. After returning to room temperature, the samples were checked for agglomeration or stratification at the initial state, 90 days and 180 days respectively. The results can be expressed as "yes / no" and the average particle size of the samples was tested. The results are shown in Table 2.
[0101] Table 2 Stability test results
[0102]
[0103]
[0104] Stability is the ability to maintain its initial properties or properties without changing over time under specified or reasonably foreseeable storage and use conditions. As shown in Table 2, after being placed at -18°C, 4°C, room temperature and 45°C for 180 days, the liposomes prepared in Examples 1-4 all showed good stability, and the particle size variation was smaller than that in Comparative Examples 1-2. It can be seen that the transdermal β-nicotinamide mononucleotide nanoliposomes provided in this application are of great significance for promoting the stability of the product. The particle size and particle size variation of the liposomes prepared in Example 1 are the smallest, and the system is the most stable, which is the best experimental effect.
[0105] Test 3: In vitro release assay
[0106] Take 1 ml of liposomes prepared in Example 1-4 and Comparative Example 1-2 and place it in a 3.5 kDa dialysis bag. After sealing, place it in a 10 ml centrifuge tube, add 3 mL of phosphate buffer solution (pH = 7.4, containing 2% Tween-80), and store it in the dark for later use. And set up an unencapsulated group with the same concentration as the control. The above samples were placed in a constant temperature shaker with a speed of 100 r / min and a temperature of 37°C. All the release medium was taken out at different time points, and an equal amount of fresh release medium was added again. The taken out release medium was measured by HPLC to calculate the NMN release content at each time point, calculate the release percentage, and draw a drug release curve. The results are as follows Figure 1 shown.
[0107] according to Figure 1 It can be seen that the drug release curve of Example 1 is the most gentle, with a cumulative release rate of 29.501% in 12 hours, followed by Example 3, Example 2, and Example 4. The percentage of release in the examples is lower than that in the comparative example. It can be seen that the transdermal β-nicotinamide mononucleotide nanoliposomes provided by the present application can significantly slow down the release rate of NMN and achieve a sustained release effect. The controlled release effect of Example 1 is the best, and it can last for a long time, significantly improving the anti-aging effect of NMN.
[0108] Test 4: Cell absorption rate experiment
[0109] The liposomes prepared in the above Examples 1-4 and Comparative Examples 1-2 were used as samples to verify the absorption of NMN encapsulated in liposomes by human skin fibroblasts (HDF). After the cells were cultured at 37°C for 24 hours, a sample labeled with the fluorescent probe coumarin was added to the DMEM complete medium. After 24 hours and 48 hours of culture, the cells were washed three times with phosphate-buffered saline. After adding 10 ml of cell lysis solution and culturing for 2 hours, the content of coumarin-labeled NMN in the cell lysate was detected. The cell absorption rate = detected NMN content / encapsulated NMN amount × 100%. The absorption of liposomes by HDF cells is shown in Figure 2. Figure 2 shown.
[0110] according to Figure 2 The test results show that after 24 hours and 48 hours of culture, the absorption rate of HDF cells for Example 1 is the highest, followed by Example 3, Example 2, and Example 4. The absorption rate of the example cells is significantly higher than that of the control example. It can be seen that the transdermal β-nicotinamide mononucleotide nanoliposomes provided in the present application can effectively promote the absorption of NMN by HDF cells, and improve the transdermal penetration bioavailability and skin retention of NMN.
[0111] Test 5: Antioxidant damage experiment
[0112] The liposomes prepared in the above Examples 1-4 and Comparative Examples 1-2 were used as samples and diluted with DMEM complete medium to a final concentration of 10%, and hydrogen peroxide was diluted to 800 μM with DMEM medium. HaCaT cells (human immortalized keratinocytes) in logarithmic growth phase were cultured at 8×10 3 Each well was inoculated with 100 μL of the system in each well of a 96-well plate. The outermost circle of the 96-well plate was sealed with 100 μL of PBS. After 24 hours, when the cells were completely attached to the wall, the culture medium containing the sample to be tested was replaced and the cells were cultured for another 24 hours. The supernatant was discarded and 800 μM hydrogen peroxide dilution was added. The model was cultured in an incubator for 4 hours. After 4 hours, the cell activity was immediately detected by CCK8 method at a detection wavelength of 450 nm. Figure 3 Results shown.
[0113] according to Figure 3 It can be seen that after hydrogen peroxide damage, the cell viability of the non-administered group was 39.41%, indicating that the hydrogen peroxide damage HaCaT model was successfully established. Compared with the H2O2 model group, the liposomes prepared in Examples 1-4 can significantly improve the viability of oxidatively damaged human immortalized keratinocytes (P < 0.0001), and the improvement effect is better than that of the comparative example, among which Example 1 has the strongest antioxidant damage performance. It can be seen that the transdermal β-nicotinamide mononucleotide nanoliposomes provided in this application have excellent effects on improving cell oxidative damage.
[0114] Test 6: Anti-aging experiment
[0115] Dilute Examples 1-4 and Comparative Examples 1-2 with DMEM complete medium at a final concentration of 1%. Human dermal fibroblasts (HDF) in logarithmic growth phase were cultured at 8×10 3 Each well was inoculated in a 96-well plate, and the system in each well was 100 μL. The outermost circle of the 96-well plate was sealed with 100 μL of PBS. After 24 hours, when the cells were completely attached to the wall, the culture medium containing the sample to be tested was replaced, and the cells were cultured for another 24 hours. Modeling was performed by UV irradiation for 7 minutes, and β-galactosidase staining was performed after 24 hours. After incubation overnight, photos were taken and recorded. The modeling group was modeled with DMEM complete culture medium and UV irradiation for 7 minutes, and the blank group was DMEM complete culture medium without UV irradiation. The results are shown in Figure 4 shown.
[0116] The β-galactosidase staining method can detect the degree of cell aging, and the lower the staining intensity, the lower the degree of aging, and the stronger the anti-aging effect of the test substance. Figure 4 It can be seen that the staining intensity of Examples 1-4 and Comparative Examples 1-2 is significantly lower than that of the model group, and the prepared products all have anti-aging properties. The staining intensity of Examples 1-4 is close to that of the blank group, among which the staining intensity of Example 1 is closest to that of the blank group, indicating that the product prepared in Example 1 has the strongest anti-aging effect. It can be seen that the transdermal β-nicotinamide mononucleotide nanoliposomes provided by the present application have excellent anti-aging effects.
[0117] Test 7: ABTS free radical scavenging experiment
[0118] The liposomes prepared in the above Examples 1-4 and Comparative Examples 1-2 were used as samples, 10 μl of the sample was mixed with 190 μl of 0.25 mmol / LABTS working solution / PBS, shaken thoroughly, incubated at room temperature for 6 minutes, and the absorbance was measured at 405 nm. The absorbance of the sample and ABTS working solution was recorded as A1, the absorbance of the sample and PBS was recorded as A2, and the absorbance of the ABTS working solution and PBS was recorded as A3. Then, the ABTS clearance rate = [1-(A1-A2) / A3]×100%. The positive control was vitamin C with a loading concentration of 200, 150, 125, 100, 75, 50, and 25 μg / mL. The IC of the positive control VC was 50 The test system is considered effective if the concentration is between 0.040 g / L and 0.070 g / L. The results are shown in Table 3 and Figure 5 shown.
[0119] Table 3 Test results of ABTS free radical scavenging
[0120]
[0121] ABTS is a free radical that can be reduced by antioxidants during oxidation. Figure 5 It can be seen that the ABTS free radical scavenging rate of Example 1 is the highest, with an average of 68.2%, followed by Example 2, Example 4, Example 3, Comparative Example 1, and Comparative Example 2, and the scavenging rates decrease in turn. The ABTS free radical scavenging rates of the examples are all higher than those of the comparative examples, which shows that the transdermal β-nicotinamide mononucleotide nanoliposomes provided by the present application can more effectively play the role of scavenging ABTS free radicals and anti-oxidation.
[0122] The various embodiments in this specification are described in a progressive manner, and the same or similar parts between the various embodiments can be referenced to each other, and each embodiment focuses on the differences from other embodiments.
[0123] The above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit the present application. Although the present application has been described in detail with reference to the aforementioned embodiments, a person of ordinary skill in the art should understand that the technical solutions recorded in the aforementioned embodiments may still be modified, or some or all of the technical features therein may be replaced by equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the present application.
Claims
1. A transdermal β-nicotinamide mononucleotide nanoliposome, It is characterized in that Its components, calculated by the total mass percentage of raw materials, include: β-Nicotinamide mononucleotide 7-25%, Phospholipids 3-5%, Cholesterol 10-25%, Macrogol Vitamin E Succinate 40-60%, Sodium cholate 3-10%, Isopropyl myristate 0.1-0.3%, The balance is water to make up to 100%; The particle size of the transdermal β-nicotinamide mononucleotide nanoliposome is 72-107 nm.
2. The transdermal β-nicotinamide mononucleotide nanoliposome according to claim 1, It is characterized in that The phospholipids are one or more of soybean lecithin, egg yolk lecithin, dipalmitoylphosphatidylcholine, dilauroylphosphatidylcholine and distearoylphosphatidylcholine.
3. The transdermal β-nicotinamide mononucleotide nanoliposome according to claim 1, It is characterized in that The mass ratio of β-nicotinamide mononucleotide to phospholipid is 1:4-15; And / or, the mass ratio of the vitamin E polyethylene glycol succinate to the phospholipid is 1:10-30; And / or, the mass ratio of cholesterol to phospholipid is 1:4-10; And / or, the mass ratio of β-nicotinamide mononucleotide to sodium cholate is 1:4; And / or, the mass ratio of β-nicotinamide mononucleotide to isopropyl myristate is 1:
2.
4. A method for preparing transdermal β-nicotinamide mononucleotide nanoliposomes according to any one of claims 1 to 3, It is characterized in that The method comprises: Dissolve phospholipids, cholesterol and polyethylene glycol vitamin E succinate in anhydrous ethanol, and perform vacuum rotary evaporation once to obtain lipid film A; Mixing sodium cholate, isopropyl myristate, the lipid film A and anhydrous ethanol, and performing secondary vacuum rotary evaporation to obtain a lipid film B; The aqueous solution of β-nicotinamide mononucleotide is mixed with the lipid film B, a phosphate buffer solution is added, ultrasonic emulsification dispersion and mixing is performed in an ice-water bath, and high-pressure homogenization is performed to obtain the transdermally absorbable β-nicotinamide mononucleotide nanoliposome.
5. The method for preparing transdermal β-nicotinamide mononucleotide nanoliposomes according to claim 4, It is characterized in that The rotation speed of the first vacuum rotary evaporation and the second vacuum rotary evaporation is 45r / min, the pressure is 0.10MPa, and the temperature is 40-50°C.
6. The method for preparing transdermal β-nicotinamide mononucleotide nanoliposomes according to claim 4, It is characterized in that When ultrasonic emulsification dispersion and mixing is performed in the ice-water bath, the emulsification power is 150-250W, the emulsification frequency is ultrasonic 4s, the interval is 2s, and the emulsification time is 2-4min.
7. The method for preparing transdermal β-nicotinamide mononucleotide nanoliposomes according to claim 4, It is characterized in that The pressure of the high-pressure homogenization treatment is 600-800 bar.
8. The method for preparing transdermal β-nicotinamide mononucleotide nanoliposomes according to claim 4, It is characterized in that The number of cycles of the high pressure homogenization treatment is 2-3 times.
9. The method for preparing transdermal β-nicotinamide mononucleotide nanoliposomes according to claim 4, It is characterized in that The concentration of the phosphate buffer solution is 0.05 mol / L and the pH is 6.0-7.
0.
10. Use of the transdermal β-nicotinamide mononucleotide nanoliposomes prepared by the preparation method according to any one of claims 4 to 9 in the preparation of medicines and skin care products.
Citation Information
Patent Citations
TPGS-containing liposome composition and application thereof
CN101991538A
Liver-targeting NMN liposome nanoparticles as well as preparation method and application thereof
CN111557910A
Cited By
Pet staple food food easy to absorb and preparation method thereof
CN119908420A
Preparation method of ABTS-HRP-based liposome bionic composite material
CN120490255A
